TGFβ2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer

TGFβ2 is an essential regulator of immune cell functionality, but the mechanisms whereby it drives immune infiltration in gastric Cancer remain uncertain. The Oncomine and Tumor Immunoassay Resource (TIMER) databases were used for assessing the expression of TGFβ2, after which TIMER was used to explore the relationship between TGFβ2 and tumour immune infiltration. Finally, we assessed how TGFβ2 expression correlated with the expression of a set of marker genes associated with immune infiltration using TIMER and GEPIA. We determined TGFβ2 expression to be significantly correlated with outcome in multiple types of Cancer in the Cancer Genome Atlas (TCGA), with the effect being particularly pronounced in gastric Cancer. Furthermore, elevated TGFβ2 expression was found to be significantly correlated with gastric Cancer N staging, and with the expression of a variety of immune markers associated with particular immune cell subsets. These results indicate that TGFΒ2 is associated with patient outcome and tumour immune cell infiltration in multiple Cancer types. This suggests that TGFβ2 is a key factor which governs immune cell recruitment to gastric Cancer tumours, potentially playing a vital role in governing immune cell infiltration and thus representing a valuable prognostic biomarker in gastric Cancer patients.

TGFβ2; gastric cancer; lymphocytes; prognosis; tumour infiltration.